xgene logo

August 23,2023

Xgene Pharmaceutical Inc. Announces Dosing of First Patient in a Phase 2b/3 Trial of XG005 for the Treatment of Pain Following Bunionectomy Surgery.

xgene logo

April 26,2023

Xgene Pharmaceutical Announces Positive Top-Line Results from Phase 1b/2a Trial of Topical Gel XG004 for the Treatment of Osteoarthritis (OA) Pain of the Knee

xgene logo

November 04,2021

Xgene Pharmaceutical secures $40m in Series C


September 22,2021

Xgene Pharmaceuticals Co. Ltd.and RaQualia Pharma Inc.have entered into a licensing agreement for a novel TRPM8 blocker discovered by RaQualia Pharma


April 22,2020

NDA Application of XG005 will follow a 505(B)(2) regulatory pathway based on FDA’S feedback


May 4, 2019

XGene Pharmaceutical Closed the B Plus

Round Financing


October 25, 2018

XGene Pharmaceutical Closed US$20 Million B Round Financing